Valuation : CSL Limited

Market Cap 59.57B 51.39B 48.41B 44.11B 82.45B 5,628B 83.07B 573B 222B 2,877B 224B 219B 9,451B P/E 2027 *
20.4x
P/E 2028 * 18.5x
Enterprise Value 68.45B 59.05B 55.63B 50.68B 94.74B 6,466B 95.45B 659B 256B 3,306B 257B 251B 10,860B EV / Sales 2027 *
4.35x
EV / Sales 2028 * 4.17x
Free-Float
99.97%
Yield 2027 *
2.42%
Yield 2028 * 2.56%
1 day+0.89%
1 week+0.12%
Current month+1.33%
1 month+41.27%
3 months+84.55%
6 months+18.46%
Current year+0.70%
1 week 170.75
Extreme 170.75
175.36
1 month 121.87
Extreme 121.87
175.97
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Director

152 0.0000%
8/21/26 Exercice

Director

244 0.0001%
8/21/26 Exercice

Director

-183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%+0.12%-17.32%-35.39% 59.05B
+3.31%+4.27%+47.02%+3.24% 82.26B
-2.94%-0.05%+518.36%+36.78% 61.59B
-1.25%-5.30%-1.98%+33.18% 51.23B
+0.92%-0.23%+11.50%+169.82% 48.3B
+3.71%+1.04%+59.98%-16.11% 31.92B
+2.19%-0.53%+48.22%+101.39% 25.34B
+0.20%+1.70%-3.42%+190.03% 22.56B
-0.52%-1.98%+65.45%+110.84% 16.56B
-0.83%-2.29%-14.71%+786.97% 15.28B
Average +0.57%-2.66%+71.31%+138.08% 41.41B
Weighted average by Cap. +0.68%-2.82%+94.53%+73.76%

Financials

2027 *2028 *
Net sales 15.75B 13.58B 12.8B 11.66B 21.79B 1,487B 21.96B 151B 58.8B 760B 59.13B 57.84B 2,498B 16.28B 14.05B 13.23B 12.06B 22.54B 1,538B 22.71B 157B 60.8B 786B 61.15B 59.81B 2,583B
Net income 2.83B 2.44B 2.3B 2.1B 3.92B 268B 3.95B 27.27B 10.58B 137B 10.64B 10.41B 450B 3.16B 2.73B 2.57B 2.34B 4.38B 299B 4.41B 30.42B 11.81B 153B 11.87B 11.61B 502B
Net Debt 8.88B 7.66B 7.21B 6.57B 12.29B 839B 12.38B 85.42B 33.15B 429B 33.34B 32.61B 1,408B 8.38B 7.23B 6.81B 6.21B 11.6B 792B 11.69B 80.63B 31.29B 405B 31.47B 30.78B 1,330B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-02 A$173.85 +0.89% 722,041
26-09-01 A$172.31 +0.43% 1,501,636
26-08-31 A$171.57 -0.44% 1,673,346
26-08-28 A$172.32 -0.90% 1,158,131
26-08-27 A$173.88 +0.84% 874,276
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
124.39USD
Average target price
118.97USD
Spread / Average Target
-4.36%

Quarterly revenue - Rate of surprise